NIAID provides research funding and resources for the scientific community to facilitate the development of vaccines, therapeutics, and diagnostics for infectious diseases, including those caused by coronaviruses.
Resources for Researchers
NIAID provides resources to advance coronavirus research and encourage product development. These resources include viral isolates and preclinical services.
- To find grant funding opportunities specific to COVID-19, search for COVID on our Opportunities page.
- You may consider other funding opportunities that allow you to propose COVID-19 research, for example, Parent Program Announcements.
- To find all NIAID contract funding opportunities, see contract solicitations.
For the latest information, read recent NIAID Funding News articles.
Request Access to NIAID COVID-19 Clinical Trials Data Sets
AccessClinicalData@NIAID is an NIAID cloud-based, secure data platform that enables sharing of and access to data sets from NIAID COVID-19 clinical trials for the basic and clinical research community. Read more about AccessClinicalData@NIAID.
Other Opportunities for Shared Data
The Seattle Structural Genomics Center for Infectious Diseases and Center for Structural Genomics of Infectious Diseases are making their data publicly available. See more information about the Centers for Research on Structural Biology of Infectious Diseases (CRSTAL-ID) in general.
Share Your Data
Connect With Other Researchers
Researchers at NIAID
When COVID-19 was identified in early 2020, NIAID intramural laboratory scientists mobilized quickly to study the virus. See a list of researchers and find out about work they are doing on COVID-19.
COVID-19 Scientific Interest Group
The COVID-19 Scientific Interest Group was created to promote collaboration and facilitate the exchange of information and resources among NIH intramural scientists and their HHS colleagues concerning research on COVID-19 and SARS-CoV-2.
NIH currently recommends that laboratories working with SARS-CoV-2 adhere to the Centers for Disease Control and Prevention (CDC) interim laboratory biosafety guidelines for collecting and handling specimens potentially containing SARS-CoV-2. In addition, all research subject to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) must be reviewed and approved by an Institutional Biosafety Committee (IBC).
Questions related to the NIH Guidelines may be addressed to NIHGuidelines@od.nih.gov.
Immune Response to COVID-19
NIAID researchers are spearheading a large, international collaboration to investigate the innate and adaptive immune responses during acute COVID-19 infection and convalescence. The overall goal is to identify immunological and virological correlates and predictors of clinical outcomes. Researchers are currently seeking physicians to collaborate.